Under the deal, both the firms will jointly evaluate certain AH proprietary probiotic technology to develop as a treatment or management of gastrointestinal (GI) conditions.
Following the completion of the programme, Norgine will have an option to negotiate a license to commercialize the technology.
The tie up allows AH to obtain upfront payment from Norgine and is eligible to get additional payments upon the completion of certain development milestones.
AH CEO Barry Kiely said this partnership is further validation of AH’s technology and recognition of their position at the forefront of research into probiotic technology.